TopFunds

ResMed

NYSE: RMD

Stock price

226.73 USD

(+0%) TODAY

Health Care EquipmentMedical - Devices
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
2.5
2.4
2.2
2.8
4.3
3.2
5.3
6.1
6.9
9.5
10.4
15.4%
02Free cash flow per share
3.4
2.4
3
2.6
4.8
4.2
1.3
3.8
8.7
11.3
11.4
12.9%
03Dividends per share
1.2
1.3
1.4
1.5
1.6
1.6
1.7
1.8
1.9
2.1
2.4
7.2%
04Dividends payout, %
47.7%
54.4%
63.2%
52.3%
36.2%
47.8%
31.5%
28.8%
27.7%
22.2%
23%
(7.1)%
PROFIT AND LOSS STATEMENT
05Revenue
1,839
2,067
2,340
2,607
2,957
3,197
3,578
4,223
4,685
5,146
5,653
11.9%
06% Change
-
-
-
-
-
-
-
-
-
-
-
11.9%
07Cost of revenue
(772.2)
(865)
(978)
(1,070)
(1,239)
(1,358)
(1,554)
(1,867)
(2,030)
(2,091)
(2,196)
11%
08Gross profit
1,067
1,202
1,362
1,537
1,718
1,839
2,024
2,356
2,655
3,055
3,458
12.5%
09% Margin
58%
58.2%
58.2%
59%
58.1%
57.5%
56.6%
55.8%
56.7%
59.4%
61.2%
58% A
10Operating expenses
(637.5)
(775.9)
(820.3)
(957.3)
(908.7)
(935.4)
(1,024)
(1,224)
(1,335)
(1,370)
(1,565)
9.4%
11% of Revenue
(34.7)%
(37.5)%
(35.1)%
(36.7)%
(30.7)%
(29.3)%
(28.6)%
(29)%
(28.5)%
(26.6)%
(27.7)%
(31.3)% A
12Operating Income
429
425.8
541.8
579.3
809.7
903.7
1,000
1,132
1,320
1,685
1,893
16%
13Income tax expense
(87.2)
(76.5)
(205.7)
(114.3)
(111.4)
(409.2)
(181)
(204.1)
(243.8)
(276.8)
(396.1)
16.4%
14Net Income
352.4
342.3
315.6
404.6
621.7
474.5
779.4
897.6
1,021
1,401
1,523
15.8%
15% Margin
19.2%
16.6%
13.5%
15.5%
21%
14.8%
21.8%
21.3%
21.8%
27.2%
26.9%
20% A
16Shares Outstanding
141.7
142.5
144
144.5
145.7
146.5
147
147.5
147.6
147.3
145
0.2%
17EPS Basic
2.5
2.4
2.2
2.8
4.3
3.3
5.3
6.1
6.9
9.6
10.4
15.3%
18EPS Diluted
2.5
2.4
2.2
2.8
4.3
3.2
5.3
6.1
6.9
9.5
10.4
15.4%
19EBITDA
522.7
568.9
680.2
705.8
990.4
1,104
1,177
1,359
1,534
1,913
2,146
15.2%
% Margin
28.4%
27.5%
29.1%
27.1%
33.5%
34.5%
32.9%
32.2%
32.7%
37.2%
38%
32.1% A
20Net Interest Income (expense)
5.7
(11.2)
(12)
(33.9)
(39.4)
(23.6)
(22.3)
(47.4)
(45.7)
(12.6)
(29)
-
21Net Debt / EBITDA
0.8
0.5
0.1
1.6
0.8
0.5
0.5
1
0.4
(0.2)
(0.3)
0.5 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
731.4
821.9
188.7
147.1
463.2
295.3
273.7
227.9
238.4
1,210
1,469
7.2%
23Short-term investments
-
-
-
-
-
-
-
-
-
-
-
-
24Accounts receivable
382.1
450.5
483.7
528.5
474.6
625.2
576
704.9
837.3
990.7
1,036
10.5%
25Other current assets
81.7
103.2
124.6
120.1
168.7
197.3
337.9
437
459.8
377.8
873.5
26.7%
26Inventory
224.5
268.3
268.7
349.6
416.9
457
743.9
998
822.3
927.7
945.8
15.5%
27Total Current Assets
1,420
1,644
1,066
1,145
1,524
1,575
1,932
2,368
2,358
3,506
4,325
11.8%
Non-Current Assets
28Net property, plant & equipment
384.3
394.2
386.6
387.5
535.7
592.1
630.5
665.8
699.1
718.3
735
6.7%
29Long-term investments
33.8
38.3
41.2
56.7
51.1
75.5
67.2
156.9
169.8
85
-
10.8%
30Other non-current assets
1,421
1,392
1,570
2,518
2,477
2,486
2,467
3,561
3,646
3,866
3,906
10.6%
31Total Non-Current Assets
1,839
1,825
1,998
2,962
3,064
3,153
3,164
4,384
4,515
4,669
4,641
9.7%
Total Assets
3,259
3,469
3,064
4,108
4,587
4,728
5,096
6,752
6,872
8,174
8,966
10.7%
LIABILITIES
Current Liabilities
32Accounts payable
92.6
92.8
92.7
115.7
135.8
138
159.2
150.8
237.7
278.2
308.9
12.8%
33Short-term debt
299.4
-
11.5
12
33.3
35.6
31.8
31.8
35.2
40.4
289.1
(0.4)%
34Other current liabilities
246
267.4
407.1
428.3
433.7
738.2
498.3
576
637.7
700.6
797.1
12.5%
35Total Current Liabilities
638
360.1
511.2
556
602.8
911.8
689.3
758.5
910.7
1,019
1,395
8.1%
Non-Current Liabilities
36Long-term debt
873.3
1,079
270
1,259
1,266
758.1
885.8
1,548
838.8
811.4
536.8
(4.8)%
37Other non-current liabilities
50.6
69.5
223.7
220.6
221.6
172.6
160
315.2
258.9
376
448.6
24.4%
38Total Non-Current Liabilities
923.9
1,148
493.7
1,480
1,488
930.7
1,046
1,863
1,098
1,187
985.4
0.7%
39Total Liabilities
1,562
1,508
1,005
2,036
2,090
1,842
1,735
2,622
2,008
2,207
2,381
4.3%
SHAREHOLDERS` EQUITY
40Common stock
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.6
0.8
0.8
3.1%
41Retained earnings / (deficit)
2,160
2,316
2,432
2,436
2,833
3,080
3,614
4,253
4,992
6,082
7,255
12.9%
42Accumulated other comprehensive income / (loss)
(222.7)
(189.1)
(224.3)
(253)
(284)
(193.5)
(312.7)
(272.5)
(251.5)
(74.7)
(82.5)
(9.5)%
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
1,695
1,960
2,059
2,072
2,497
2,886
3,361
4,130
4,864
5,968
6,585
14.5%
45Total Liabilities and shareholders' Equity
3,257
3,469
3,064
4,108
4,587
4,728
5,096
6,752
6,872
8,174
8,966
10.7%
46Total Debt
1,173
1,079
281.5
1,271
1,299
793.7
917.6
1,580
873.9
851.8
825.9
(3.5)%
47Net Debt
441.3
256.7
92.8
1,124
836.1
498.4
643.8
1,352
635.6
(357.6)
(643.3)
-
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
352.4
342.3
315.6
404.6
621.7
474.5
779.4
897.6
1,021
1,401
1,523
15.8%
49Depreciation & amortization
86.8
112.2
120
150.8
181.4
191.5
193.8
197.6
216.2
235.8
244.2
10.9%
50Share-based compensation expense
46.4
45.9
48.4
52.1
57.6
63.9
65.3
71.1
80.2
91.7
104.3
8.4%
51Changes in working capital and other assets
62.3
(86.3)
21.1
(148.4)
(58.4)
6.8
(687.4)
(473)
83.9
23.4
(66)
-
52Net cash flows from operating activities
547.9
414.1
505
459.1
802.3
736.7
351.1
693.3
1,401
1,752
1,806
12.7%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(67.8)
(71.5)
(71.5)
(77.3)
(105.9)
(116.8)
(156)
(134)
(99.5)
(89.9)
(156.3)
8.7%
54Purchases of investments / marketable securities
(16.5)
(6.5)
(29.5)
(47)
(46)
(21.8)
(20.7)
(32.2)
(22.5)
(6.4)
(28.5)
5.6%
55Proceeds from maturities of marketable securities
0.5
3.3
(9)
8.6
10.6
-
6.8
3.9
1
-
2.8
19.4%
56Other investing activities
(1,042)
(7.3)
8.1
(960)
(38.5)
(19.8)
(60)
(997.6)
(148.9)
(103.8)
(363.1)
(10)%
57Net cash flows from investing activities
(1,126)
(81.9)
(101.8)
(1,076)
(179.9)
(158.5)
(229.9)
(1,160)
(269.8)
(200)
(545.2)
(7)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(74.4)
30.2
(30.5)
13.9
48.2
37.8
47.4
49.1
(96.9)
(225.6)
(625.5)
23.7%
59Dividends paid, net
(168.1)
(186.3)
(199.5)
(211.7)
(225.1)
(226.7)
(245.3)
(258.3)
(282.3)
(310.9)
(349.7)
7.6%
60Debt issuance (repayments), net
856.3
(95)
(796.2)
807.5
(94)
(522)
122
665
(730)
(40)
(10)
-
61Other financing activities
(1.2)
(11.7)
(0.5)
(29)
(46.4)
(53.7)
(52.4)
(33)
(10)
(29.8)
(21.8)
33.4%
62Net cash flows from financing activities
612.6
(262.9)
(1,027)
580.6
(317.3)
(764.6)
(128.4)
422.9
(1,119)
(606.3)
(1,007)
-
63Increase (decrease) in cash and cash equivalents
14.2
90.5
(633.2)
(41.6)
316
(167.9)
(21.6)
(45.8)
10.5
971.1
259.8
33.8%
64Cash and equivalents, ending balance
731.4
821.9
188.7
147.1
463.2
295.3
273.7
227.9
238.4
1,210
1,469
7.2%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
480.1
342.6
433.6
381.7
696.3
619.9
195.1
559.3
1,302
1,662
1,650
13.1%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
20262025202420232022202120202019201820172016

ResMed (RMD) financial statements and performance

Explore ResMed (RMD) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.